Skip to main content
. 2017 Sep 4;6(9):e376. doi: 10.1038/oncsis.2017.75

Figure 9.

Figure 9

Regulation between β-hCG, BRCA1 and TGFβRII in breast cancer. (a) Cell viability assay (MTS) of HCC1937 and MCF7 cells upon treating with TGFβRII inhibitor, SB-431542 for 48 h. (b) Summary of regulation between β-hCG and BRCA1 and possible tumorigenesis in BRCA1 defective breast tumors. *indicates the possible targets for effective inhibition of tumorigenesis in BRCA1 mutated cancer cells.